A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

Last updated: December 19, 2025
Sponsor: Kezar Life Sciences, Inc.
Overall Status: Completed

Phase

2

Condition

Liver Disease

Hepatitis

Liver Disorders

Treatment

placebo

zetomipzomib in open-label extension

zetomipzomib

Clinical Study ID

NCT05569759
KZR-616-208
  • Ages > 18
  • All Genders

Study Summary

This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

Eligibility Criteria

Inclusion

Key Inclusion Criteria for the Double-blind Treatment Period:

  • Must be aged ≥18 years.

  • Must have a clinical diagnosis of AIH and signs of active disease despite standard-of-care therapy for ≥3 months or disease flare after experiencing complete remission induced by standard-of-care treatment, including:

  • Screening ALT values that are 1.25 to 10 times the upper limit of the normal range (ULN)

  • Liver biopsy results with Ishak score (modified HAI) ≥5/18 indicating active AIH, from a biopsy performed at Screening, or within 6 months prior to Screening

  • Mild or no hepatic impairment (Child Pugh category A)

  • Must be willing to use and taper glucocorticoid therapy.

  • Must be willing to use effective contraception.

Key Exclusion Criteria for the Double-blind Treatment Period:

  • Have a concomitant diagnosis of primary biliary sclerosis, primary sclerosing cholangitis, IgG 4 related cholangitis, drug related AIH (at Screening) or a history of drug-related AIH.

  • Have clinical evidence of significant unstable or uncontrolled diseases other than the disease under study.

  • Are receiving oral or injectable immunomodulating treatment for any other autoimmune disease prior to enrollment in the study. Patients who have been using such treatments must follow the specified washout periods.

  • Have an active infection (eg, acute hepatitis E, cytomegalovirus, or Epstein-Barr virus) requiring systemic therapy with antibiotic, antiviral, or antifungal treatment, or has had any febrile illness within 7 days prior to Day -1.

  • Have a history of thyroiditis, celiac disease, or other autoimmune disorder known to be associated with transaminitis.

  • Have liver cirrhosis with significant impairment of liver function (Child Pugh category B or C) or have decompensated cirrhosis.

  • Patients with histology confirmed coincident non-alcoholic steatohepatitis.

Key Inclusion Criteria for the Open-label Extension Period:

  • Same as Double-blind Treatment Period inclusion criteria, except the following modifications:

  • ALT value can be normal or, if elevated, in the range of 1.25 to 10 times the upper limit of normal

  • Must have completed the Double-blind Period study visits through Week 24, including all Week 24 Visit assessments.

  • Must be willing to maintain glucocorticoid therapy or continue to taper glucocorticoid therapy.

Key Exclusion Criteria for the Open-label Extension Period:

• Same as Double-blind Treatment Period except no need to re-test for HIV, HBV, HCV, and TB.

Study Design

Total Participants: 24
Treatment Group(s): 3
Primary Treatment: placebo
Phase: 2
Study Start date:
May 23, 2023
Estimated Completion Date:
April 30, 2025

Study Description

This was a Phase 2a, multi-center, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate safety, tolerability, and efficacy of zetomipzomib in patients with autoimmune hepatitis (AIH) who have not benefited from standard-of-care treatment, had an incomplete response to ≥3 months of standard-of-care treatment, or had a disease flare after standard of care.

Zetomipzomib or placebo were administered weekly for a 24-week treatment period in addition to standard-of-care (glucocorticoids), followed by a 4-week off-treatment safety follow-up period. Zetomipzomib and placebo was administered subcutaneously (SC) once weekly.

At the end of the 24-week treatment period, eligible participants from both the zetomipzomib- and placebo-treated arms who completed the double-blind treatment period could enroll in the open-label extension period to receive up to an additional 24 weeks of treatment with zetomipzomib.

Connect with a study center

  • Mayo Clinic Arizona

    Phoenix 5308655, Arizona 5551752 85054
    United States

    Site Not Available

  • Keck School of Medicine of USC

    Los Angeles 5368361, California 5332921 90033
    United States

    Site Not Available

  • University of California, Los Angeles

    Los Angeles 5368361, California 5332921 90095
    United States

    Site Not Available

  • Stanford Medicine

    Redwood City 5386834, California 5332921 94063
    United States

    Site Not Available

  • California Pacific Medical Center

    San Francisco 5391959, California 5332921 94109
    United States

    Site Not Available

  • University of California, San Francisco

    San Francisco 5391959, California 5332921 94132
    United States

    Site Not Available

  • University of Colorado

    Aurora 5412347, Colorado 5417618 80045
    United States

    Site Not Available

  • Yale University

    New Haven 4839366, Connecticut 4831725 06510
    United States

    Site Not Available

  • Mayo Clinic Florida

    Jacksonville 4160021, Florida 4155751 32224
    United States

    Site Not Available

  • University of Miami

    Miami 4164138, Florida 4155751 33136
    United States

    Site Not Available

  • Northwestern University

    Chicago 4887398, Illinois 4896861 60611
    United States

    Site Not Available

  • Rush University

    Chicago 4887398, Illinois 4896861 60612
    United States

    Site Not Available

  • Indiana University

    Indianapolis 4259418, Indiana 4921868 46202
    United States

    Site Not Available

  • Ochsner Clinic Foundation

    New Orleans 4335045, Louisiana 4331987 70121
    United States

    Site Not Available

  • Beth Israel Deaconess Medical Center

    Boston 4930956, Massachusetts 6254926 02215
    United States

    Site Not Available

  • Massachusetts General Hospital

    Boston 4930956, Massachusetts 6254926 02114
    United States

    Site Not Available

  • University of Michigan Medical Center

    Ann Arbor 4984247, Michigan 5001836 48109
    United States

    Site Not Available

  • Washington University School of Medicine

    St Louis 4407066, Missouri 4398678 63110
    United States

    Site Not Available

  • Northwell Health Center for Liver Disease and Transplantation

    Manhasset 5125766, New York 5128638 11030
    United States

    Site Not Available

  • New York University Langone Health/Grossman School of Medicine

    New York 5128581, New York 5128638 10016
    United States

    Site Not Available

  • Duke University Medical Center

    Durham 4464368, North Carolina 4482348 27710
    United States

    Site Not Available

  • University Hospitals Cleveland Medical Center

    Cleveland 5150529, Ohio 5165418 44106
    United States

    Site Not Available

  • University of Pennsylvania

    Philadelphia 4560349, Pennsylvania 6254927 19104
    United States

    Site Not Available

  • Virginia Commonwealth University

    Richmond 4781708, Virginia 6254928 23298
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.